Initial clinical data demonstrated 71% ACR50 response in refractory rheumatoid arthritis (RA) patients with at least six ...

The agency explicitly stated that the trial’s current primary endpoint is “not an appropriate endpoint to demonstrate efficacy.” ・As a result, the FDA no longer considers the study to be “pivotal.” ...

Initial clinical data demonstrated 71% ACR50 response in refractory rheumatoid arthritis (RA) patients with at least six months of follow-up in the company-sponsored Phase 2a basket trial, with no pat ...

Initial AlloNK® (AB-101) clinical data demonstrated 71% ACR50 response in refractory rheumatoid arthritis (RA) patients with at least six months ...

Artiva Biotherapeutics (ARTV) is maintained as a "Buy," driven by FDA alignment for a single phase 3 trial of AlloNK plus ...

The head of the CDC invented a new standard to stop the publication of studies showing COVID-19 vaccines had major benefits with minimal risk.

When my one-month-old daughter was diagnosed with biliary atresia — a rare disease that for most of human history was ...

Topline results for the randomized portion of PALISADE-4 are expected in the second quarter of 2026SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage ...

Trial misses goal: Tonabersat did not significantly reduce central retinal thickness versus placebo after six months in the overall study population. Signals in subgroups: Analyses indicated greater ...

Detailed price information for Caribou Biosciences Inc (CRBU-Q) from The Globe and Mail including charting and trades.

Stimulating the brain's self-control center via rTMS reduces smoking by 11 cigarettes a day, outperforming reward-suppression tactics.

VYVGART and VYVGART Hytrulo are the first and only approved treatments for all serotypes of adult patients living with gMG – anti-AChR-Ab positive, anti-MuSK-Ab positive, anti-LRP4-Ab positive, and ...